2022 World Conference on Lung Cancer (ePosters)-EP08.01-033. ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC

EP08.01-033. ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC

Back to course

Pdf Summary

This study examined the outcomes and genetic profiles of Chinese patients with advanced non-small cell lung cancer (NSCLC) who were treated with Atezolizumab, a global approved treatment for NSCLC. The study included patients who had previously received 1-2 lines of therapy, including those who are often excluded from pivotal trials. <br /><br />A total of 101 patients were enrolled in the study, and their baseline characteristics were analyzed. The median progression-free survival (PFS) was 2.9 months, and the median overall survival (OS) was 15.3 months. The best overall response rate was 15.5% in the evaluable population. <br /><br />Biomarker analysis was conducted on tumor biopsies from 31 patients. The most commonly altered genes were TP53, TTN, MUC19, MUC16, and PTGER4. PRRC2C and ZMYND8 gene mutations were significantly enriched in Atezolizumab responders compared to non-responders. Mutations in ATXN7, KCNB1, STK11, and XAB2 were associated with worse PFS. A cutoff of 10% of CD8 TILs (Tumor-infiltrating lymphocytes) was associated with PFS. <br /><br />The study concluded that Atezolizumab showed clinically meaningful benefits in Chinese patients with advanced NSCLC and provided insights into biomarkers that may predict response to treatment. These results may guide future therapeutic strategies. The study was sponsored by Shanghai Roche Pharmaceuticals Ltd. <br /><br />It is important to note that this is a preliminary analysis and further research is needed to validate the findings.

Asset Subtitle

Yun Fan

Meta Tag

Speaker Yun Fan

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Chinese patients

advanced non-small cell lung cancer

NSCLC

Atezolizumab

treatment outcomes

genetic profiles

progression-free survival

overall survival

biomarker analysis

gene mutations